Drugs / OCU-10-C-110
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05904691 | Nov 2023 → Nov 2026 expected | wet macular degeneration | Ocugenix Corporation | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCU-10-C-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05904691 ↗ |
| Route | Intravitreal | “single intravitreal dose” NCT05904691 ↗ |